Olmesartan/Amlodipine Zentiva Pharma (Olmesartan Medoxomil, Amlodipine)

Olmesartan/Amlodipine combines two antihypertensive agents that act on the renin‑angiotensin system and vascular smooth‑muscle tone.

• Hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient.
• Hypertension with high cardiovascular risk: helps achieve target blood pressure in patients with additional risk factors.
• Resistant hypertension: offers an oral combination option for patients who need multiple mechanisms of action.

• Olmesartan medoxil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release, while amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The fixed‑dose combination therefore lowers systemic vascular resistance and reduces blood pressure through complementary pathways.

Adverse reactions may occur with any antihypertensive combination and should be monitored.

Common Side Effects

• Dizziness or light‑headedness
• Peripheral edema
• Headache
• Flushing
• Fatigue
• Nausea

Serious or Rare Side Effects

• Angio‑edema
• Severe hypotension
• Hepatic enzyme elevation
• Acute kidney injury
• Myocardial infarction in susceptible patients
• Severe allergic reactions (anaphylaxis)

When using Olmesartan/Amlodipine, clinicians should consider several safety aspects.

• Monitor blood pressure: ensure adequate control without excessive lowering.
• Renal function: assess creatinine and electrolytes before and during therapy.
• Hepatic function: check liver enzymes in patients with liver disease.
• Pregnancy: avoid use; teratogenic risk is associated with angiotensin‑receptor blockers.
• Concomitant potassium‑sparing diuretics: watch for hyperkalaemia.
• Store below 25°C: keep in the original packaging, protect from moisture and light.

Olmesartan/Amlodipine may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of renal impairment and hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase amlodipine levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function.
• Diuretics: may potentiate hypotensive response.
• Lithium: increased risk of lithium toxicity.
• Simvastatin: higher amlodipine concentrations can raise statin levels.
• Rifampicin: may reduce amlodipine exposure.